{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:27Z","timestamp":1791245187316,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2790,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1093\/annonc\/mdr348","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T01:51:23Z","timestamp":1312941083000},"page":"897-902","source":"Crossref","is-referenced-by-count":119,"title":["Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors"],"prefix":"10.1016","volume":"23","author":[{"given":"C.","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"De Mattos-Arruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Carreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"S\u00e1nchez-Oll\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Baselga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Di Cosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr348_bb0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1093\/annonc\/mdr348_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1990.8.1.103","article-title":"Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer","volume":"8","author":"Paik","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1093\/annonc\/mdr348_bb0025","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","article-title":"Humanization of an anti-p185HER2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdr348_bb0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr348_bb0035","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr348_bb0045","author":"Slamon"},{"key":"10.1093\/annonc\/mdr348_bb0050","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr348_bb0055","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr348_bb0060","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdr348_bb0065","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","article-title":"Clinical cardiac tolerability of trastuzumab","volume":"22","author":"Perez","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0070","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0075","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0080","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0085","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0090","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0095","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0100","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0105","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1093\/annonc\/mdr348_bb0110","article-title":"Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (> 70 years)","volume":"26","author":"Brunello","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0115","article-title":"Trastuzumab (H) benefits both younger and older women with HER2 positive MBC","volume":"22","author":"Paton","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0120","article-title":"Survival benefit of traztuzumab (Herceptin) and chemotherapy in older (age>60) patients","volume":"20","author":"Fyfe","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0125","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mdr348_bb0130","series-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"New York Heart Association","year":"1973"},{"key":"10.1093\/annonc\/mdr348_bb0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.6004\/jnccn.2009.0012","article-title":"Breast cancer. Clinical practice guidelines in oncology","volume":"7","author":"Carlson","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdr348_bb0140","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8588(05)70274-4","article-title":"Cancer and aging. An evolving panorama","volume":"14","author":"Balducci","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1093\/annonc\/mdr348_bb0150","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.285.7.885","article-title":"Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older","volume":"285","author":"Yancik","year":"2001","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdr348_bb0155","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0160","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","article-title":"Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdr348_bb0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","article-title":"Cardiotoxicity profile of trastuzumab","volume":"31","author":"Ewer","year":"2008","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mdr348_bb0175","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9149(76)90061-8","article-title":"A general cardiovascular risk profile: the Framingham Study","volume":"38","author":"Kannel","year":"1976","journal-title":"Am J Cardiol"},{"key":"10.1093\/annonc\/mdr348_bb0180","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1093\/annonc\/mdr348_bb0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1093\/annonc\/mdr348_bb0190","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1093\/annonc\/mdr348_bb0195","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0200","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa020265","article-title":"Long-term trends in the incidence of and survival with heart failure","volume":"347","author":"Levy","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr348_bb0205","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr348_bb0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pcad.2010.04.002","article-title":"Role of biomarkers in chemotherapy-induced cardiotoxicity","volume":"53","author":"Cardinale","year":"2010","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/4\/897\/547150\/mdr348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T09:14:44Z","timestamp":1627463684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0923753419346484"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr348","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13357373.14726775","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}